BindingDB logo
myBDB logout

BDBM50221815 4-({[(6-{N-[(1S)-5-amino-1-carbamoylpentyl]-1-[(3S)-1-[(2S)-5-carbamimidamido-2-[(2S)-3-carbamoyl-2-[(2S)-4-carbamoyl-2-[(2S)-2-[(2R)-3-(4-hydroxyphenyl)-2-[3-(4-hydroxyphenyl)-N-methylpropanamido]propanamido]-3-phenylpropanamido]butanamido]propanamido]pentanoyl]pyrrolidin-3-yl]formamido}-6-oxohexyl)carbamoyl]methyl}sulfanyl)-2,3,5-trichloro-6-(2,2,4,8,10,10-hexamethyl-12,14-disulfonato-2,3,4,7,7a,8,9,10,12,12a-decahydro-1H-13-oxa-1,11-diazapentacen-6-yl)benzoate::CID44428106::[Lys8(Alexa 488)]PVA

SMILES: [#6]-[#6]-1-[#6]C([#6])([#6])[#7]=[#6]-2-[#6]-1-[#6]-[#6]-1=[#6](-c3cc4-[#6](-[#6])-[#6]C([#6])([#6])[#7]-c4c(c3-[#8]-[#6]-1-[#6]-2S([#8-])(=O)=O)S([#8-])(=O)=O)-c1c(Cl)c(-[#16]-[#6]-[#6](=O)-[#7]-[#6]-[#6]-[#6]-[#6]-[#6]-[#6](=O)-[#7](-[#6@@H](-[#6]-[#6]-[#6]-[#6]-[#7])-[#6](-[#7])=O)-[#6](=O)-[#6@H]-2-[#6]-[#6]-[#7](-[#6]-2)-[#6](=O)-[#6@H](-[#6]-[#6]-[#6]\[#7]=[#6](\[#7])-[#7])-[#7]-[#6](=O)-[#6@H](-[#6]-[#6](-[#7])=O)-[#7]-[#6](=O)-[#6@H](-[#6]-[#6]-[#6](-[#7])=O)-[#7]-[#6](=O)-[#6@H](-[#6]-c2ccccc2)-[#7]-[#6](=O)-[#6@@H](-[#6]-c2ccc(-[#8])cc2)-[#7](-[#6])-[#6](=O)-[#6]-[#6]-c2ccc(-[#8])cc2)c(Cl)c(Cl)c1-[#6](-[#8-])=O

InChI Key: InChIKey=SVLGRIWNJNOFJU-CRAMPYNJSA-K

Data: 4 KI

Find this compound or compounds like it in BindingDB or PDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 4 hits for monomerid = 50221815   
Target/Host
(Institution)
LigandTarget/Host
Links
Ligand
Links
Trg + Lig
Links
Ki
nM
ΔG°
kcal/mole
IC50
nM
Kd
nM
EC50/IC50
nM
koff
s-1
kon
M-1s-1
pHTemp
°C
Vasopressin V1a receptor


(Homo sapiens (Human))
BDBM50221815
PNG
(4-({[(6-{N-[(1S)-5-amino-1-carbamoylpentyl]-1-[(3S...)
Show SMILES [#6]-[#6]-1-[#6]C([#6])([#6])[#7]=[#6]-2-[#6]-1-[#6]-[#6]-1=[#6](-c3cc4-[#6](-[#6])-[#6]C([#6])([#6])[#7]-c4c(c3-[#8]-[#6]-1-[#6]-2S([#8-])(=O)=O)S([#8-])(=O)=O)-c1c(Cl)c(-[#16]-[#6]-[#6](=O)-[#7]-[#6]-[#6]-[#6]-[#6]-[#6]-[#6](=O)-[#7](-[#6@@H](-[#6]-[#6]-[#6]-[#6]-[#7])-[#6](-[#7])=O)-[#6](=O)-[#6@H]-2-[#6]-[#6]-[#7](-[#6]-2)-[#6](=O)-[#6@H](-[#6]-[#6]-[#6]\[#7]=[#6](\[#7])-[#7])-[#7]-[#6](=O)-[#6@H](-[#6]-[#6](-[#7])=O)-[#7]-[#6](=O)-[#6@H](-[#6]-[#6]-[#6](-[#7])=O)-[#7]-[#6](=O)-[#6@H](-[#6]-c2ccccc2)-[#7]-[#6](=O)-[#6@@H](-[#6]-c2ccc(-[#8])cc2)-[#7](-[#6])-[#6](=O)-[#6]-[#6]-c2ccc(-[#8])cc2)c(Cl)c(Cl)c1-[#6](-[#8-])=O |c:6,t:11|
Show InChI InChI=1S/C94H122Cl3N17O23S3/c1-48-44-93(3,4)110-77-56(48)41-58-71(59-42-57-49(2)45-94(5,6)111-78(57)83(140(134,135)136)80(59)137-79(58)82(77)139(131,132)133)72-73(91(129)130)74(95)76(97)81(75(72)96)138-47-68(119)104-36-15-9-12-21-70(121)114(64(84(101)122)20-13-14-35-98)89(127)53-34-38-113(46-53)90(128)61(19-16-37-105-92(102)103)107-87(125)63(43-67(100)118)108-85(123)60(31-32-66(99)117)106-86(124)62(39-51-17-10-8-11-18-51)109-88(126)65(40-52-24-29-55(116)30-25-52)112(7)69(120)33-26-50-22-27-54(115)28-23-50/h8,10-11,17-18,22-25,27-30,41,48-49,53,57,60-65,80,83,110,115-116H,9,12-16,19-21,26,31-40,42-47,98H2,1-7H3,(H2,99,117)(H2,100,118)(H2,101,122)(H,104,119)(H,106,124)(H,107,125)(H,108,123)(H,109,126)(H,129,130)(H4,102,103,105)(H,131,132,133)(H,134,135,136)/p-3/t48?,49?,53-,57?,60-,61-,62-,63-,64-,65+,80?,83?/m0/s1
PDB

UniProtKB/SwissProt
UniProtKB/TrEMBL

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

Article
PubMed
0.0900n/an/an/an/an/an/an/an/a



INSERM

Curated by ChEMBL


Assay Description
Displacement of [3H]AVP from human vasopressin V1a receptor expressed in CHO cells


J Med Chem 50: 4976-85 (2007)


Article DOI: 10.1021/jm061404q
BindingDB Entry DOI: 10.7270/Q24X58NW
More data for this
Ligand-Target Pair
Oxytocin receptor


(Homo sapiens (Human))
BDBM50221815
PNG
(4-({[(6-{N-[(1S)-5-amino-1-carbamoylpentyl]-1-[(3S...)
Show SMILES [#6]-[#6]-1-[#6]C([#6])([#6])[#7]=[#6]-2-[#6]-1-[#6]-[#6]-1=[#6](-c3cc4-[#6](-[#6])-[#6]C([#6])([#6])[#7]-c4c(c3-[#8]-[#6]-1-[#6]-2S([#8-])(=O)=O)S([#8-])(=O)=O)-c1c(Cl)c(-[#16]-[#6]-[#6](=O)-[#7]-[#6]-[#6]-[#6]-[#6]-[#6]-[#6](=O)-[#7](-[#6@@H](-[#6]-[#6]-[#6]-[#6]-[#7])-[#6](-[#7])=O)-[#6](=O)-[#6@H]-2-[#6]-[#6]-[#7](-[#6]-2)-[#6](=O)-[#6@H](-[#6]-[#6]-[#6]\[#7]=[#6](\[#7])-[#7])-[#7]-[#6](=O)-[#6@H](-[#6]-[#6](-[#7])=O)-[#7]-[#6](=O)-[#6@H](-[#6]-[#6]-[#6](-[#7])=O)-[#7]-[#6](=O)-[#6@H](-[#6]-c2ccccc2)-[#7]-[#6](=O)-[#6@@H](-[#6]-c2ccc(-[#8])cc2)-[#7](-[#6])-[#6](=O)-[#6]-[#6]-c2ccc(-[#8])cc2)c(Cl)c(Cl)c1-[#6](-[#8-])=O |c:6,t:11|
Show InChI InChI=1S/C94H122Cl3N17O23S3/c1-48-44-93(3,4)110-77-56(48)41-58-71(59-42-57-49(2)45-94(5,6)111-78(57)83(140(134,135)136)80(59)137-79(58)82(77)139(131,132)133)72-73(91(129)130)74(95)76(97)81(75(72)96)138-47-68(119)104-36-15-9-12-21-70(121)114(64(84(101)122)20-13-14-35-98)89(127)53-34-38-113(46-53)90(128)61(19-16-37-105-92(102)103)107-87(125)63(43-67(100)118)108-85(123)60(31-32-66(99)117)106-86(124)62(39-51-17-10-8-11-18-51)109-88(126)65(40-52-24-29-55(116)30-25-52)112(7)69(120)33-26-50-22-27-54(115)28-23-50/h8,10-11,17-18,22-25,27-30,41,48-49,53,57,60-65,80,83,110,115-116H,9,12-16,19-21,26,31-40,42-47,98H2,1-7H3,(H2,99,117)(H2,100,118)(H2,101,122)(H,104,119)(H,106,124)(H,107,125)(H,108,123)(H,109,126)(H,129,130)(H4,102,103,105)(H,131,132,133)(H,134,135,136)/p-3/t48?,49?,53-,57?,60-,61-,62-,63-,64-,65+,80?,83?/m0/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt
UniProtKB/TrEMBL

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

Article
PubMed
1.04n/an/an/an/an/an/an/an/a



INSERM

Curated by ChEMBL


Assay Description
Displacement of [3H]AVP from human oxytocin receptor expressed in CHO cells


J Med Chem 50: 4976-85 (2007)


Article DOI: 10.1021/jm061404q
BindingDB Entry DOI: 10.7270/Q24X58NW
More data for this
Ligand-Target Pair
Vasopressin V1b receptor


(Homo sapiens (Human))
BDBM50221815
PNG
(4-({[(6-{N-[(1S)-5-amino-1-carbamoylpentyl]-1-[(3S...)
Show SMILES [#6]-[#6]-1-[#6]C([#6])([#6])[#7]=[#6]-2-[#6]-1-[#6]-[#6]-1=[#6](-c3cc4-[#6](-[#6])-[#6]C([#6])([#6])[#7]-c4c(c3-[#8]-[#6]-1-[#6]-2S([#8-])(=O)=O)S([#8-])(=O)=O)-c1c(Cl)c(-[#16]-[#6]-[#6](=O)-[#7]-[#6]-[#6]-[#6]-[#6]-[#6]-[#6](=O)-[#7](-[#6@@H](-[#6]-[#6]-[#6]-[#6]-[#7])-[#6](-[#7])=O)-[#6](=O)-[#6@H]-2-[#6]-[#6]-[#7](-[#6]-2)-[#6](=O)-[#6@H](-[#6]-[#6]-[#6]\[#7]=[#6](\[#7])-[#7])-[#7]-[#6](=O)-[#6@H](-[#6]-[#6](-[#7])=O)-[#7]-[#6](=O)-[#6@H](-[#6]-[#6]-[#6](-[#7])=O)-[#7]-[#6](=O)-[#6@H](-[#6]-c2ccccc2)-[#7]-[#6](=O)-[#6@@H](-[#6]-c2ccc(-[#8])cc2)-[#7](-[#6])-[#6](=O)-[#6]-[#6]-c2ccc(-[#8])cc2)c(Cl)c(Cl)c1-[#6](-[#8-])=O |c:6,t:11|
Show InChI InChI=1S/C94H122Cl3N17O23S3/c1-48-44-93(3,4)110-77-56(48)41-58-71(59-42-57-49(2)45-94(5,6)111-78(57)83(140(134,135)136)80(59)137-79(58)82(77)139(131,132)133)72-73(91(129)130)74(95)76(97)81(75(72)96)138-47-68(119)104-36-15-9-12-21-70(121)114(64(84(101)122)20-13-14-35-98)89(127)53-34-38-113(46-53)90(128)61(19-16-37-105-92(102)103)107-87(125)63(43-67(100)118)108-85(123)60(31-32-66(99)117)106-86(124)62(39-51-17-10-8-11-18-51)109-88(126)65(40-52-24-29-55(116)30-25-52)112(7)69(120)33-26-50-22-27-54(115)28-23-50/h8,10-11,17-18,22-25,27-30,41,48-49,53,57,60-65,80,83,110,115-116H,9,12-16,19-21,26,31-40,42-47,98H2,1-7H3,(H2,99,117)(H2,100,118)(H2,101,122)(H,104,119)(H,106,124)(H,107,125)(H,108,123)(H,109,126)(H,129,130)(H4,102,103,105)(H,131,132,133)(H,134,135,136)/p-3/t48?,49?,53-,57?,60-,61-,62-,63-,64-,65+,80?,83?/m0/s1
UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

Article
PubMed
100n/an/an/an/an/an/an/an/a



INSERM

Curated by ChEMBL


Assay Description
Displacement of [3H]AVP from human vasopressin V1b receptor expressed in CHO cells


J Med Chem 50: 4976-85 (2007)


Article DOI: 10.1021/jm061404q
BindingDB Entry DOI: 10.7270/Q24X58NW
More data for this
Ligand-Target Pair
Vasopressin V2 receptor


(Homo sapiens (Human))
BDBM50221815
PNG
(4-({[(6-{N-[(1S)-5-amino-1-carbamoylpentyl]-1-[(3S...)
Show SMILES [#6]-[#6]-1-[#6]C([#6])([#6])[#7]=[#6]-2-[#6]-1-[#6]-[#6]-1=[#6](-c3cc4-[#6](-[#6])-[#6]C([#6])([#6])[#7]-c4c(c3-[#8]-[#6]-1-[#6]-2S([#8-])(=O)=O)S([#8-])(=O)=O)-c1c(Cl)c(-[#16]-[#6]-[#6](=O)-[#7]-[#6]-[#6]-[#6]-[#6]-[#6]-[#6](=O)-[#7](-[#6@@H](-[#6]-[#6]-[#6]-[#6]-[#7])-[#6](-[#7])=O)-[#6](=O)-[#6@H]-2-[#6]-[#6]-[#7](-[#6]-2)-[#6](=O)-[#6@H](-[#6]-[#6]-[#6]\[#7]=[#6](\[#7])-[#7])-[#7]-[#6](=O)-[#6@H](-[#6]-[#6](-[#7])=O)-[#7]-[#6](=O)-[#6@H](-[#6]-[#6]-[#6](-[#7])=O)-[#7]-[#6](=O)-[#6@H](-[#6]-c2ccccc2)-[#7]-[#6](=O)-[#6@@H](-[#6]-c2ccc(-[#8])cc2)-[#7](-[#6])-[#6](=O)-[#6]-[#6]-c2ccc(-[#8])cc2)c(Cl)c(Cl)c1-[#6](-[#8-])=O |c:6,t:11|
Show InChI InChI=1S/C94H122Cl3N17O23S3/c1-48-44-93(3,4)110-77-56(48)41-58-71(59-42-57-49(2)45-94(5,6)111-78(57)83(140(134,135)136)80(59)137-79(58)82(77)139(131,132)133)72-73(91(129)130)74(95)76(97)81(75(72)96)138-47-68(119)104-36-15-9-12-21-70(121)114(64(84(101)122)20-13-14-35-98)89(127)53-34-38-113(46-53)90(128)61(19-16-37-105-92(102)103)107-87(125)63(43-67(100)118)108-85(123)60(31-32-66(99)117)106-86(124)62(39-51-17-10-8-11-18-51)109-88(126)65(40-52-24-29-55(116)30-25-52)112(7)69(120)33-26-50-22-27-54(115)28-23-50/h8,10-11,17-18,22-25,27-30,41,48-49,53,57,60-65,80,83,110,115-116H,9,12-16,19-21,26,31-40,42-47,98H2,1-7H3,(H2,99,117)(H2,100,118)(H2,101,122)(H,104,119)(H,106,124)(H,107,125)(H,108,123)(H,109,126)(H,129,130)(H4,102,103,105)(H,131,132,133)(H,134,135,136)/p-3/t48?,49?,53-,57?,60-,61-,62-,63-,64-,65+,80?,83?/m0/s1
PDB

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

Article
PubMed
>1.00E+3n/an/an/an/an/an/an/an/a



INSERM

Curated by ChEMBL


Assay Description
Displacement of [3H]AVP from human vasopressin V2 receptor expressed in CHO cells


J Med Chem 50: 4976-85 (2007)


Article DOI: 10.1021/jm061404q
BindingDB Entry DOI: 10.7270/Q24X58NW
More data for this
Ligand-Target Pair